Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line.

Daisuke Yasuda,Tomoyuki Ohe,Kyoko Takahashi,Riyo Imamura,Hirotatsu Kojima,Takayoshi Okabe,Yoshinobu Ichimura,Masaaki Komatsu,Masayuki Yamamoto,Tetsuo Nagano,Tadahiko Mashino

Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line.

2020

Daisuke Yasuda
Tomoyuki Ohe
Kyoko Takahashi
Riyo Imamura
Hirotatsu Kojima
Takayoshi Okabe
Yoshinobu Ichimura
Masaaki Komatsu
Masayuki Yamamoto
Tetsuo Nagano
Tadahiko Mashino

AbstractResistance to anticancer agents has been an obstacle to developing therapeutics and reducing medical costs. Whereas sorafenib is used for the treatment of human hepatocellular carcinoma (HC...

Keywords:

Hepatocellular carcinoma
Cancer research
Protein–protein interaction
Biochemistry
Phosphorylation
Cell culture
Chemistry
Sorafenib
Diabetes mellitus
KEAP1
hepatic carcinoma
medical costs

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations